A two‐gene prognosis risk model revealed that, compared to patients with lower co‐expression, those with higher co‐expression of ATF4 and NF‐κB2 showed a significantly stronger correlation with worsened relapse, metastasis, and reduced overall survival in patients with breast cancer (Figure 6L–N), ACC, osteosarcoma, glioma, and KIRC (Figure S4H–K, Supporting Information). This evidence concerns the gene NFKB2 and osteosarcoma.